Cancer neoantigens derived from random somatic mutations in tumor tissue represent an attractive type of target for the cancer vaccine. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. As a leader in pre-clinical vaccine development and production, Creative Biolabs is confident in offering the best development services for mRNA cancer vaccines. We combine the traditional as well as the advanced genetic engineering technologies to efficiently develop highly immunogenic mRNA vaccines addressing your urgent needs.
Application of mRNA Cancer Vaccines
The most straightforward use of mRNA vaccines in oncologic settings is the immunization of patients with mRNA vaccines encoding tumor-associated antigens (TAAs). The second application of mRNA vaccines is the production of personalized vaccines against various cancers. Apart from being used directly to vaccinate patients, mRNAs can also be used in cellular therapies to transfect patient-derived cells in vitro and infuse the manipulated cells back into the patient. One such application is the transfection of patient-derived dendritic cells (DCs) with mRNAs encoding TAAs, which leads to the presentation of TAA-derived peptides on the DCs and activation of antigen-specific T cells in vivo. A second application is the transfection of patient-derived T cells with mRNAs encoding chimeric antigen receptors, which allows the T cells to directly recognize a specific antigen expressed on the tumor.
Learn more: mrna based vaccines
